Ivonescimab Application Scope

It asco is approved in China for use in combination with pemetrexed and carboplatin for the treatment of patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after tyrosine kinase inhibitor (TKI) therapy.

Ivonescimab Characteristics

Ingredients: The active ingredient is ivonescimab, with excipients including histidine, histidine hydrochloride, sucrose, polysorbate 80 (II), and water for injection.
Properties: It is a colorless to pale yellow, clear liquid, which may be slightly opalescent.
Specification: Specific dosage strengths and formulations are detailed in the official prescribing information.
Packaging Specification: Details regarding packaging are provided in the official prescribing information.
Storage: Storage conditions are specified in the official prescribing information.
Expiry Date: The shelf life is indicated on the product packaging.
Executive Standard: It meets the standards set by the National Medical Products Administration (NMPA) of China.
Approval Number: The approval number is available in the official documentation.
Date of Revision: The date of the latest revision is noted in the prescribing information.
Manufacturer: Akeso Biopharma.

Guidelines for the Use of Ivonescimab

Dosage and Administration: The recommended dosage of it in the approved setting is 20 mg/kg administered intravenously over 60 minutes once every three weeks, until disease progression or unacceptable toxicity occurs. It should be administered first, followed by chemotherapy, with an interval of at least 30 minutes between the two treatments.
Adverse Reactions: Common adverse reactions include fatigue, hypertension, and decreased appetite. Detailed information on adverse reactions is provided in the prescribing information.
Contraindications: Contraindications are specified in the official prescribing information.
Precautions: Precautions, including monitoring requirements and management of specific adverse reactions, are detailed in the prescribing information.

Ivonescimab Interactions

Drug Interactions: Information on potential drug interactions is provided in the prescribing information.

For comprehensive and specific information, please refer to the official prescribing information provided by the manufacturer.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from Hong Kong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.